High Performance, Quantitative Breast PET Scanner Integrated with Tomosynthesis

与断层合成集成的高性能、定量乳房 PET 扫描仪

• 批准号: 9236176
• 负责人: Suleman Surti
• 金额: $ 67.98万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-04-01 至 2021-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9236176
• 关键词: Algorithms; Area; Biopsy; Breast; Breast Cancer Early Detection; Breast Cancer Patient; Breast Cancer Treatment; Breast Cancer therapy; Calibration; Cancer Patient; Clinical; Clinical Research; Custom; Data; Detection; Development; Devices; Diagnosis; Diagnostic; Diagnostic Imaging; Digital Breast Tomosynthesis; Early treatment; Emergency Department patient; Engineering; Environment; FPS-FES Oncogene; Future; Image; Immunohistochemistry; In Vitro; Institution; Lesion; Malignant Neoplasms; Measurement; Measures; Modality; Monitor; Multimodal Imaging; Oncologist; PET/CT scan; Pathology; Patients; Performance; Photons; Pilot Projects; Play; Positron-Emission Tomography; Primary Neoplasm; Research; Resolution; Role; Surgeon; System; Systemic Therapy; Systems Development; Techniques; Testing; Time; Tissue Sample; Translating; Tumor Biology; Tumor stage; Woman; Work; anatomic imaging; attenuation; base; breast cancer diagnosis; breast imaging; breast lesion; cancer therapy; clinical imaging; clinical practice; cost; cost effective; data acquisition; design; detector; flexibility; fluorodeoxyglucose; image reconstruction; imaging biomarker; imaging capabilities; imaging study; improved; malignant breast neoplasm; molecular imaging; mortality; multidisciplinary; operation; outcome forecast; personalized medicine; precision medicine; public health relevance; quantitative imaging; research clinical testing; response; screening; targeted treatment; tomosynthesis; tumor; uptake

 DESCRIPTION (provided by applicant): The objective of this work is the development of a flexible, high performance, dedicated breast PET-DBT scanner that is used in early-stage primary tumor characterization, in diagnostic imaging of patients with suspicious, early-stage cancer, as well as in assessing tumor response to therapy. The design allows full integration of a high performance breast PET scanner with a DBT unit for multi-modality imaging. In order to achieve this objective the dedicated scanner will be developed to provide quantitative PET images with fully corrected data co-registered with DBT images. Commercial whole-body PET/CT scanners are limited in their performance when imaging small (< 2 cm in size), early stage tumors or for detecting small changes in tumor uptake. Dedicated breast PET scanners, on the other hand, have been geared more towards lesion detection (patient screening) and do not emphasize the quantitative imaging capability of these systems that is needed for personalized therapy. Our aims are to: (i) develop a high spatial resolution and high sensitivity, quantitative breast PET scanner that is integrated with a DBT system, (ii) conduct pilot clinical studies to characterize early stage breast cancer and perform diagnostic imaging in patients with dense breasts, and (iii) help determine role of high performance, dedicated breast PET-DBT in personalized breast cancer treatment. The clinical studies will involve two clinical scenarios: characterization of early stage, ER+ breast cancer using 18F- fluoroestradiol, and diagnostic 18F-fluordeoxyglucose imaging in patients with dense breasts. In the first aim we will complete a full assembly of the PET-DBT device with a dedicated data acquisition system and customized gantry. In the second and third aims we will first optimize data correction and calibration techniques that have been developed for image quantitation, followed by system characterization and optimization for clinical imaging. In the fourth aim we plan on performing two clinical studies (each with up to 20 patients) to compare and correlate quantitative results from the dedicated breast PET scanner to those obtained from whole-body PET, as well as in vitro results from pathology. At the end of the study we expect to have demonstrated the role a high resolution, dedicated breast PET-DBT scanner can play in the future for personalized breast cancer treatment.

 描述(申请人提供)：这项工作的目标是开发一种灵活的、高性能的专用乳腺PET-DBT扫描仪，用于早期原发肿瘤的表征，用于可疑的早期癌症患者的诊断成像，以及评估肿瘤对治疗的反应。该设计允许将高性能的乳腺PET扫描仪与用于多模式成像的DBT单元完全集成。为了实现这一目标，将开发专用扫描仪，以提供具有与DBT图像共同配准的完全校正数据的定量PET图像。商用全身PET/CT扫描仪在成像小肿瘤(2厘米大小)、早期肿瘤或检测肿瘤摄取的微小变化时，其性能有限。另一方面，专用的乳腺PET扫描仪更多地面向病变检测(患者筛查)，而不强调个性化治疗所需的这些系统的定量成像能力。我们的目标是：(I)开发高空间分辨率和高灵敏度， 该系统将主要用于：(I)开发与DBT系统集成的定量乳腺PET扫描仪；(Ii)进行试点临床研究，以确定早期乳腺癌的特征，并对乳房致密的患者进行诊断成像；(Iii)帮助确定高性能、专用乳腺PET-DBT在个性化乳腺癌治疗中的作用。临床研究将涉及两种临床方案：使用18F-氟雌二醇诊断早期ER+乳腺癌，以及对乳房致密患者进行诊断18F-脱氧葡萄糖成像。在第一个目标中，我们将完成带有专用数据采集系统和定制机架的PET-DBT设备的完整组装。在第二和第三个目标中，我们将首先优化已为图像量化开发的数据校正和校准技术，然后是临床成像的系统表征和优化。在第四个目标中，我们计划进行两项临床研究(每项研究最多20名患者)，以比较和关联来自专用乳腺PET扫描仪的定量结果与全身PET获得的定量结果，以及来自病理学的体外结果。在研究结束时，我们希望展示一种高分辨率、专用的乳腺PET-DBT扫描仪在未来个性化乳腺癌治疗中的作用。